233 related articles for article (PubMed ID: 33095415)
1. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D; Chinen Y; Isa R; Fujibayashi Y; Kuwahara-Ota S; Yamaguchi J; Takimoto-Shimomura T; Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Taniwaki M; Handa H; Kuroda J
Int J Hematol; 2021 Mar; 113(3):381-394. PubMed ID: 33095415
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
4. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
5. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.
Chi J; Ballabio E; Chen XH; Kušec R; Taylor S; Hay D; Tramonti D; Saunders NJ; Littlewood T; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Lawrie CH
Biol Direct; 2011 May; 6():23. PubMed ID: 21592325
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
Tatekawa S; Chinen Y; Ri M; Narita T; Shimura Y; Matsumura-Kimoto Y; Tsukamoto T; Kobayashi T; Kawata E; Uoshima N; Taki T; Taniwaki M; Handa H; Iida S; Kuroda J
Br J Haematol; 2017 Aug; 178(4):534-546. PubMed ID: 28439875
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
Roccaro AM; Sacco A; Thompson B; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem MR; Lin CP; Ribatti D; Rollins BJ; Witzig TE; Anderson KC; Ghobrial IM
Blood; 2009 Jun; 113(26):6669-80. PubMed ID: 19401561
[TBL] [Abstract][Full Text] [Related]
9. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.
Bolzoni M; Chiu M; Accardi F; Vescovini R; Airoldi I; Storti P; Todoerti K; Agnelli L; Missale G; Andreoli R; Bianchi MG; Allegri M; Barilli A; Nicolini F; Cavalli A; Costa F; Marchica V; Toscani D; Mancini C; Martella E; Dall'Asta V; Donofrio G; Aversa F; Bussolati O; Giuliani N
Blood; 2016 Aug; 128(5):667-79. PubMed ID: 27268090
[TBL] [Abstract][Full Text] [Related]
10. Nestin expression throughout multistep pathogenesis of multiple myeloma.
Svachova H; Kryukov F; Kryukova E; Sevcikova S; Nemec P; Greslikova H; Rihova L; Kubiczkova L; Hajek R
Br J Haematol; 2014 Mar; 164(5):701-9. PubMed ID: 24329895
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Handa H; Kuroda Y; Kimura K; Masuda Y; Hattori H; Alkebsi L; Matsumoto M; Kasamatsu T; Kobayashi N; Tahara KI; Takizawa M; Koiso H; Ishizaki T; Shimizu H; Yokohama A; Tsukamoto N; Saito T; Murakami H
Br J Haematol; 2017 Nov; 179(3):449-460. PubMed ID: 28770558
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Fagerli UM; Holt RU; Holien T; Vaatsveen TK; Zhan F; Egeberg KW; Barlogie B; Waage A; Aarset H; Dai HY; Shaughnessy JD; Sundan A; Børset M
Blood; 2008 Jan; 111(2):806-15. PubMed ID: 17934070
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of telomere-associated genes in multiple myeloma.
Díaz de la Guardia R; Catalina P; Panero J; Elosua C; Pulgarin A; López MB; Ayllón V; Ligero G; Slavutsky I; Leone PE
J Cell Mol Med; 2012 Dec; 16(12):3009-21. PubMed ID: 22947336
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of miR-144/199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling.
Gupta N; Kumar R; Sharma A
Mol Cell Biochem; 2021 Jun; 476(6):2551-2559. PubMed ID: 33649985
[TBL] [Abstract][Full Text] [Related]
16. Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders.
Panero J; Stella F; Schutz N; Fantl DB; Slavutsky I
PLoS One; 2015; 10(9):e0137972. PubMed ID: 26366868
[TBL] [Abstract][Full Text] [Related]
17. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
18. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
19.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
20. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
